Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • 17 hours ago

NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC

Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.

Zacks Investment Research • Jun 8, 2026

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insi.

Business Wire • Jun 4, 2026

Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)

Most investors' portfolios hold at least a couple of the market's biggest companies, just because these names are best-known to most investors. These crowded trades in already-massive companies, however, can mean their potential upside is limited.

The Motley Fool • Jun 3, 2026

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. “Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board,” said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. “Their deep expertise across evidence.

Business Wire • Jun 3, 2026

NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

Zacks Investment Research • Jun 1, 2026

Why Natera Is My Favorite Stock Idea for the Rest of 2026

It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.

24/7 Wall Street • May 29, 2026

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy.

Business Wire • May 29, 2026

Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

Zacks Investment Research • May 28, 2026

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer. The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediat.

Business Wire • May 28, 2026